← Eichor
Study identifier: NCT06793670 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Landiolol in Mitral Valve Surgery

Condition: Cardiac Failure · Low Cardiac Output Syndrome  ·  Sponsor: Università Vita-Salute San Raffaele

PhasePhase 4
Planned participants1500
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Chronic mitral regurgitation is the most common valvular abnormality worldwide, it occurs in 10% of the general population and its prevalence increases with age. When left untreated, it can lead to left ventricular dysfunction and cause disabling symptoms (e.g., fatigue and dyspnea), life-threatening complications (e.g., ventricular dilation, congestive heart failure) and death. Surgical correction of chronic mitral regurgitation before irreversible changes happen can be curative. Open surgical valve repair or replacement are accomplished through cardiopulmonary bypass and cardioplegic arrest. Myocardial protection is essential to guarantee an uneventful perioperative course since a not-well protected heart may lead to postoperative low-cardiac output syndrome. This occurs in 30% of high-risk patients who undergo elective cardiac surgery and is associated with 20% mortality. Cardioplegia preserves the heart during ischemic arrest by reducing its metabolic demand. The most effective cardioplegia for protection in adult cardiac surgery remains unknown and improving the protection of the heart during the ischemic arrest may potentially improve patients' postoperative outcomes. Pharmacological adjuvants to the cardioplegic solutions have been tested to mitigate the ischaemic-reperfusion injury following cardiac surgery. Ultra-short acting beta-blockers (e.g., esmolol, landiolol) decrease intraoperative myocardial metabolic demand and suppress the sympathetic response to surgical …

This description comes directly from the study's public registry record.

Talk to the study team

Fabrizio Monaco, MD  ·  0226436154  ·  monaco.fabrizio@hsr.it

Giovanni Landoni, Prof.  ·  0226436154  ·  landoni.giovanni@hsr.it

Always discuss trial participation with your own doctor first.

Locations (13)

Ospedale Cesare ArrigoAlessandria, Piedmont, ItalyRecruiting
A. O. Ordine Mauriziano di TorinoTorino, TO, ItalyRecruiting
AOU di AlessandriaAlessandria, ItalyRecruiting
Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco"Catania, ItalyRecruiting
AOU CareggiFlorence, ItalyRecruiting
Azienda Ospedaliero Universitaria Ospedali Riuniti di FoggiaFoggia, ItalyRecruiting
IRCCS San Martino di GenovaGenova, ItalyRecruiting
Ospedale San RaffaeleMilan, ItalyRecruiting
ASST Grande Ospedale Metropolitano NiguardaMilan, ItalyRecruiting
AOU Policlinico Paolo GiacconePalermo, ItalyRecruiting
Azienda Ospedaliero Universitaria PisanaPisa, ItalyRecruiting
AOR San CarloPotenza, ItalyRecruiting

+ 1 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06793670